Cargando…
GSK923295 as a potential antihepatocellular carcinoma agent causing delay on liver regeneration after partial hepatectomy
BACKGROUND: The clinical trials emerged centromere protein E inhibitor GSK923295 as a promising anticancer drug, but its function in hepatocellular carcinoma (HCC) remain needs to be fully elucidated, especially as chemotherapy after hepatectomy for liver tumors. We aimed to describe anti-HCC activi...
Autores principales: | Tang, Jia-Cheng, Wu, Ke, Zheng, Xing, Xu, Ming, Dai, Yi, Wei, Sai-Sai, Cai, Xiu-Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595801/ https://www.ncbi.nlm.nih.gov/pubmed/30681497 http://dx.doi.org/10.1097/CM9.0000000000000053 |
Ejemplares similares
-
Cenp-E inhibitor GSK923295: Novel synthetic route and use as a tool to generate aneuploidy
por: Bennett, Ailsa, et al.
Publicado: (2015) -
Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract
por: Kuo, Zong-Keng, et al.
Publicado: (2016) -
Partial hepatectomy induces delayed hepatocyte proliferation and normal liver regeneration in ovariectomized mice
por: Umeda, Makoto, et al.
Publicado: (2015) -
Delayed Liver Regeneration after Partial Hepatectomy
in Aged Nos2 Knockout Mice
por: Li, Deming, et al.
Publicado: (2017) -
Biomechanics in liver regeneration after partial hepatectomy
por: Wu, Yi, et al.
Publicado: (2023)